Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
28
RNAC Quote, Financials, Valuation and Earnings
Last price:
$7.43
Seasonality move
:
-8.81%
Day range:
$7.00 - $7.82
52-week range:
$5.98 - $18.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
84.79x
P/B ratio:
568.21x
Volume:
97.9K
Avg. volume:
114.5K
1-year change:
-59.66%
Market cap:
$197.6M
Revenue:
$38.9M
EPS (TTM):
-$2.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
$100.2K | -$0.79 | -83.77% | -15.55% | $35.57 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 4.63% | 9.11% | $88.39 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
$7.60 | $35.57 | $197.6M | -- | $0.00 | 0% | 84.79x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.81 | $31.80 | $3.9B | 9.97x | $0.00 | 0% | 3.61x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$325.07 | $457.00 | $43.1B | 144.02x | $0.00 | 0% | 11.68x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.74 | $88.39 | $11.5B | 33.53x | $0.00 | 0% | 3.58x |
|
IMNN
Imunon, Inc.
|
$3.29 | $21.50 | $7M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$6.01 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
-54.23% | 1.327 | 4.74% | 10.44x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.788 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.412 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
$452K | -$21.1M | -- | -- | -4660.62% | -$20.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Cartesian Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RNAC or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of 96.33%. Cartesian Therapeutics, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About RNAC or ACAD?
Cartesian Therapeutics, Inc. has a consensus price target of $35.57, signalling upside risk potential of 368.05%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 39.41%. Given that Cartesian Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is RNAC or ACAD More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.568, which suggesting that the stock is 43.183% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock RNAC or ACAD?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or ACAD?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 84.79x versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.84.79x -- $452K -$35.9M ACADACADIA Pharmaceuticals, Inc.3.61x 9.97x $284M $273.6M
-
Which has Higher Returns RNAC or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of 16.99%. Cartesian Therapeutics, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About RNAC or ALNY?
Cartesian Therapeutics, Inc. has a consensus price target of $35.57, signalling upside risk potential of 368.05%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 40.59%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is RNAC or ALNY More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.568, which suggesting that the stock is 43.183% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock RNAC or ALNY?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or ALNY?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 144.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 84.79x versus 11.68x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.84.79x -- $452K -$35.9M ALNYAlnylam Pharmaceuticals, Inc.11.68x 144.02x $1.1B $186.4M
-
Which has Higher Returns RNAC or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of -5.2%. Cartesian Therapeutics, Inc.'s return on equity of -- beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About RNAC or BMRN?
Cartesian Therapeutics, Inc. has a consensus price target of $35.57, signalling upside risk potential of 368.05%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.39 which suggests that it could grow by 47.96%. Given that Cartesian Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is RNAC or BMRN More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.568, which suggesting that the stock is 43.183% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.229%.
-
Which is a Better Dividend Stock RNAC or BMRN?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or BMRN?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Cartesian Therapeutics, Inc.'s net income of -$35.9M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 33.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 84.79x versus 3.58x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.84.79x -- $452K -$35.9M BMRNBioMarin Pharmaceutical, Inc.3.58x 33.53x $895M -$46.6M
-
Which has Higher Returns RNAC or IMNN?
Imunon, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About RNAC or IMNN?
Cartesian Therapeutics, Inc. has a consensus price target of $35.57, signalling upside risk potential of 368.05%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 553.5%. Given that Imunon, Inc. has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Imunon, Inc. is more attractive than Cartesian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 IMNNImunon, Inc.3 1 0 -
Is RNAC or IMNN More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.568, which suggesting that the stock is 43.183% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.057, suggesting its more volatile than the S&P 500 by 105.729%.
-
Which is a Better Dividend Stock RNAC or IMNN?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or IMNN?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Imunon, Inc. quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 84.79x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.84.79x -- $452K -$35.9M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns RNAC or SVRA?
Savara, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital RNACCartesian Therapeutics, Inc.-97.65% -$1.38 -$23.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About RNAC or SVRA?
Cartesian Therapeutics, Inc. has a consensus price target of $35.57, signalling upside risk potential of 368.05%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.91%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNACCartesian Therapeutics, Inc.6 2 0 SVRASavara, Inc.6 0 0 -
Is RNAC or SVRA More Risky?
Cartesian Therapeutics, Inc. has a beta of 0.568, which suggesting that the stock is 43.183% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock RNAC or SVRA?
Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAC or SVRA?
Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Savara, Inc. quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than Savara, Inc.'s net income of -$29.6M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 84.79x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNACCartesian Therapeutics, Inc.84.79x -- $452K -$35.9M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
